Physician profile
Mark V Burns
NPI 1184731325
$3,007.00
in general payments reported to CMS, 2019-2025
19 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $122 · 2021: $259 · 2022: $615 · 2023: $513 · 2024: $560 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.66 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $539.43 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $486.22 | 2019-2025 | Veklury |
| Abbvie INC. | $290.12 | 2021-2025 | Avycaz, Teflaro |
| Pfizer INC. | $279.43 | 2019-2025 | |
| Shionogi INC | $199.23 | 2023-2025 | Fetroja |
| Insmed, INC. | $197.54 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $185.61 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $168.23 | 2020-2024 | Orbactiv, Kimyrsa, Vabomere |
| Boston Scientific Corporation | $143.50 | 2022 | |
| Janssen Biotech, INC. | $96.93 | 2019-2020 | |
| Allergan, INC. | $72.78 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $66.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $58.35 | 2023-2025 | Rebyota |
| Paratek Pharmaceuticals, INC. | $57.01 | 2022-2024 | Nuzyra |
| Biosense Webster, INC. | $56.29 | 2021-2025 | Carto 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $48.48 | 2019-2025 | Dovato |
| Novavax INC | $23.43 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Aimmune Therapeutics, INC. | $23.02 | 2023 | |
| Oxford Immunotec USA INC | $15.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.